Rotavirus vaccine - Current status and future prospects

被引:3
作者
Bernstein, DI [1 ]
机构
[1] Childrens Hosp, Med Ctr, Div Infect Dis, Cincinnati, OH 45229 USA
关键词
D O I
10.2165/00063030-200014050-00001
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Rotavirus is the most important cause of severe gastroenteritis in infants and children worldwide. Efforts to develop a vaccine have concentrated on live oral vaccines, especially with attenuated animal viruses. Because studies with rhesus monkey rotavirus and bovine rotavirus RIT 4237 or WC3 were inconsistent, reassortant rhesus and bovine vaccines have been developed that include the gene encoding the neutralising protein, VP7, of several human strains. These efforts culminated in the licensure of a tetravalent rhesus rotavirus vaccine, in 1998. Subsequent reports linking vaccination to intussusception, however, led to withdrawal of this vaccine. Trials, nevertheless, continue with an oral bovine reassortant vaccine and an attenuated human strain, 89-12. Other strategies in preclinical development include the use of virus-like particles, DNA vaccines and subunit vaccines given by mucosal and nonmucosal routes.
引用
收藏
页码:275 / 281
页数:7
相关论文
共 76 条
[1]  
Abramson JS, 1999, PEDIATRICS, V104, P575
[2]   Age-dependent diarrhea induced by a rotaviral nonstructural glycoprotein [J].
Ball, JM ;
Tian, P ;
Zeng, CQY ;
Morris, AP ;
Estes, MK .
SCIENCE, 1996, 272 (5258) :101-104
[3]   Phase 1 trial of a candidate rotavirus vaccine (RV3) derived from a human neonate [J].
Barnes, GL ;
Lund, JS ;
Adams, L ;
Mora, A ;
Mitchell, SV ;
Caples, A ;
Bishop, RF .
JOURNAL OF PAEDIATRICS AND CHILD HEALTH, 1997, 33 (04) :300-304
[4]   EVALUATION OF RHESUS ROTAVIRUS MONOVALENT AND TETRAVALENT REASSORTANT VACCINES IN US CHILDREN [J].
BERNSTEIN, DI ;
GLASS, RI ;
RODGERS, G ;
DAVIDSON, BL ;
SACK, DA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1995, 273 (15) :1191-1196
[5]   Efficacy of live, attenuated, human rotavirus vaccine 89-12 in infants: a randomised placebo-controlled trial [J].
Bernstein, DI ;
Sack, DA ;
Rothstein, E ;
Reisinger, K ;
Smith, VE ;
O'Sullivan, D ;
Spriggs, DR ;
Ward, RL .
LANCET, 1999, 354 (9175) :287-290
[6]   Safety and immunogenicity of live, attenuated human rotavirus vaccine 89-12 [J].
Bernstein, DI ;
Smith, VE ;
Sherwood, JR ;
Schiff, GM ;
Sander, DS ;
DeFeudis, D ;
Spriggs, DR ;
Ward, RL .
VACCINE, 1998, 16 (04) :381-387
[7]   EVALUATION OF WC3 ROTAVIRUS VACCINE AND CORRELATES OF PROTECTION IN HEALTHY INFANTS [J].
BERNSTEIN, DI ;
SMITH, VE ;
SANDER, DS ;
PAX, KA ;
SCHIFF, GM ;
WARD, RL .
JOURNAL OF INFECTIOUS DISEASES, 1990, 162 (05) :1055-1062
[8]   PROTECTION FROM ROTAVIRUS REINFECTION - 2-YEAR PROSPECTIVE-STUDY [J].
BERNSTEIN, DI ;
SANDER, DS ;
SMITH, VE ;
SCHIFF, GM ;
WARD, RL .
JOURNAL OF INFECTIOUS DISEASES, 1991, 164 (02) :277-283
[9]  
BERNSTEIN DI, 1997, TXB PEDIAT INFECT DI, P1901
[10]   DEVELOPMENT OF CANDIDATE ROTAVIRUS VACCINES [J].
BISHOP, RF .
VACCINE, 1993, 11 (02) :247-254